Intralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars.
keloid
pentoxifylline
triamcinolone acetonide
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
24
05
2021
received:
24
02
2021
accepted:
14
06
2021
pubmed:
18
6
2021
medline:
21
10
2021
entrez:
17
6
2021
Statut:
ppublish
Résumé
Keloids are common fibroproliferative tumors, and their treatment still represents a dilemma. Intralesional triamcinolone acetonide (TAC) injection is effective, but frequently associated with side effects. Pentoxifyllin (PTX) is a vasodilator, anti-inflammatory, and antifibrotic agent. Its intralesional injection in keloids has not been evaluated yet. Evaluating the efficacy and safety of intralesional PTX versus intralesional TAC and their combination for treatment of keloids. Thirty patients with keloids were divided into three equal groups and treated by intralesional injection of TAC, PTX, or their combination (admixed in 1:1 ratio). Injections were repeated every 3 weeks until lesional flattening or for maximum of 5 sessions. The evaluation was done using the Vancouver Scar Scale and the Verbal Rating Scale for pain and itching. A significant improvement in VSS was detected in all groups. Significantly better improvements in keloid height, pliability, pain, and itching were detected in the TAC and combination groups than in the PTX group. There was a significantly higher incidence of side effects (atrophy, hypopigmentation, telangiectasia, and precipitation of TAC) in the TAC group than in the combination group, while no side effects were reported in the PTX group. A statistically significant reduction in the number of treatment sessions (required to achieve best results) was detected in patients in the combination group. Intralesional injection of PTX is a potentially helpful, safe, and well-tolerated therapeutic tool for keloids, but with lower efficacy than intralesional TAC when used solely. Combining PTX and TAC produces significantly better results for keloid treatment and lowers the risk of TAC-induced side effects.
Sections du résumé
BACKGROUND
BACKGROUND
Keloids are common fibroproliferative tumors, and their treatment still represents a dilemma. Intralesional triamcinolone acetonide (TAC) injection is effective, but frequently associated with side effects. Pentoxifyllin (PTX) is a vasodilator, anti-inflammatory, and antifibrotic agent. Its intralesional injection in keloids has not been evaluated yet.
AIMS
OBJECTIVE
Evaluating the efficacy and safety of intralesional PTX versus intralesional TAC and their combination for treatment of keloids.
PATIENTS/METHODS
METHODS
Thirty patients with keloids were divided into three equal groups and treated by intralesional injection of TAC, PTX, or their combination (admixed in 1:1 ratio). Injections were repeated every 3 weeks until lesional flattening or for maximum of 5 sessions. The evaluation was done using the Vancouver Scar Scale and the Verbal Rating Scale for pain and itching.
RESULTS
RESULTS
A significant improvement in VSS was detected in all groups. Significantly better improvements in keloid height, pliability, pain, and itching were detected in the TAC and combination groups than in the PTX group. There was a significantly higher incidence of side effects (atrophy, hypopigmentation, telangiectasia, and precipitation of TAC) in the TAC group than in the combination group, while no side effects were reported in the PTX group. A statistically significant reduction in the number of treatment sessions (required to achieve best results) was detected in patients in the combination group.
CONCLUSIONS
CONCLUSIONS
Intralesional injection of PTX is a potentially helpful, safe, and well-tolerated therapeutic tool for keloids, but with lower efficacy than intralesional TAC when used solely. Combining PTX and TAC produces significantly better results for keloid treatment and lowers the risk of TAC-induced side effects.
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Pentoxifylline
SD6QCT3TSU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3330-3340Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18(3):606.
Tsai CH, Ogawa R. Keloid research: current status and future directions. Scars Burn Heal. 2019;5:2059513119868659.
Noishiki C, Takagi G, Kubota Y, et al. Endothelial dysfunction may promote keloid growth. Wound Repair Regen. 2017;25(6):976-983.
Bijlard E, Kouwenberg C, Timman R, et al. Burden of keloid disease: a cross-sectional health-related quality of life assessment. Acta Derm Venereol. 2017;97(2):225-229.
Limmer EE, Glass DA 2nd. A review of current keloid management: mainstay monotherapies and emerging approaches. Dermatol Ther (Heidelb). 2020;10(5):931-948.
Morelli Coppola M, Salzillo R, Segreto F, et al. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:387-396.
Ward A, Pentoxifylline CSP. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50-97.
Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol. 1990;123:339-346.
Tan A, Martinez Luna O, Glass DA 2nd. Pentoxifylline for the prevention of postsurgical keloid recurrence. Dermatol Surg. 2020;46(10):1353-1356.
Sullivan T, Smith J, Kermode J, et al. Cour temanch DJ. Rating the burn scar. J Burn Care Rehabil. 1990;11:256-260.
Breivik EK, Björnsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22-28.
Lee YI, Kim J, Yang CE, et al. Combined therapeutic strategies for keloid treatment. Dermatol Surg. 2019;45(6):802-810.
Limandjaja GC, Niessen FB, Scheper RJ, et al. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol. 2020;8:360.
Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560-571.
Smith JF, Shindel AW, Huang Y-C, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. 2011;13(2):322-325.
Fischer M, Wohlrab J, Marsch W. Crux medicorum ulcerated radiation-induced fibrosis-successful therapy with pentoxifylline and vitamin E. Eur J Dermatol. 2001;11(1):38-40.
Aronoff SC, Quinn FJ Jr, Carpenter LS, Novick WJ Jr. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr. 1994;125(6 Pt 1):992-997.
Kaya V, Yazkan R, Yıldırım M, et al. The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study. Med Sci Monit. 2014;21(20):290-296.
Liu J, Chen F, Wei Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis. Oral Dis. 2018;24(5):706-716.
Isaac C, Carvalho VF, Paggiaro AO, de Maio M, Ferreira MC. Intralesional pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic scars. Burns. 2010;36(6):831-835.
Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, sleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol. 1990;123(3):339-346.
Rawlins JM, Lam WL, Karoo RO, Naylor IL, Sharpe DT. Pentoxifylline inhibits mature burn scar fibroblasts in culture. Burns. 2006;32(1):42-45.
Noishiki C, Hayasaka Y, Ogawa R. Sex differences in keloidogenesis: an analysis of 1659 keloid patients in Japan. Dermatol Ther (Heidelb). 2019;9(4):747-754.
Kouotou EA, Nansseu JR, Omona Guissana E, et al. Epidemiology and clinical features of keloids in Black Africans: a nested case-control study from Yaoundé. Cameroon. Int J Dermatol. 2019;58(10):1135-1140.
Srivastava S, Patil A, Prakash C, et al. Comparison of intralesional triamcinolone acetonide, 5-fluorouracil, and their combination in treatment of keloids. World J Plast Surg. 2018;7(2):212-219.
Al-Attar A, Mess S, Thomassen JM, et al. Keloidpathogenesis and treatment. Plast Reconstr Surg. 2006;117:286-300.
Ahmadi M, Khalili H. Potential benefits of pentoxifylline on wound healing. Expert Rev Clin Pharmacol. 2016;9(1):129-142.
Wu W-S, Wang F-S, Yang KD, et al. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol. 2006;126(6):1264-1271.
Henderson J, Terenghi G, McGrouther DA, et al. The reinnervation pattern of wounds and scars may explain their sensory symptoms. J Plast Reconstr Aesthet Surg. 2006;59(9):942-950.
Hosseini F, Mohammadbeigi A, Aghaali M, et al. Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: a randomized trial. J Res Med Sci. 2019;24:89.
Jull A, Waters J, Aroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet. 2002;359:1550-1554.
Mikhael NW, El-Esawy FM. Intralesional pentoxifylline in the treatment of lepromatous ulcers. J Egypt Womenʼs Dermatologic Soc. 2015;12(2):102-107.
Benzon H, Chew T-L, McCarthy R, et al. Comparison of the particle sizes of different steroids and the effect of dilution: a review of the relative neurotoxicities of the steroids. Anesthesiology. 2007;106(2):331-338.
Acosta S, Ureta E, Yañez R, et al. Effectiveness of intralesional triamcinolone in the treatment of keloids in children. Pediatr Dermatol. 2016;33(1):75-79.
Searle T, Ali FR, Al-Niaimi F. The role of pharmacogenetics in keloid scar treatment: a literature review. Scars Burn Heal. 2020;6:2059513120941704.